Zepp Health Non-GAAP EPADS of -$0.79, revenue of $63.53M; gives Q3 outlook

Zepp Health reported a 7% rise in revenue for Q2 2026, reaching $64 million, but this growth was accompanied by widening losses, with adjusted net losses increasing to $12.5 million for the quarter and $30.5 million for the half-year. The company's shares dropped by 6.64% to $4.50 in regular trading before recovering slightly to $4.58 in after-hours trading, reflecting investor concerns about profitability despite the revenue increase.

Zepp Health attributed the revenue growth to higher average selling prices and a focus on premium products, while operating expenses surged due to aggressive product launches. Despite supply constraints earlier in the year, revenue for Amazfit-branded wearables grew 6.9% year-over-year, reaching $64 million, but overall unit shipments decreased from 0.7 million to 0.6 million.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.